John has a unique career mix of science, alliance management, and business development that has delivered drugs for clinical development, managed international R&D alliances, transacted major licensing and partnership deals, and launched a handful of startups. He is currently the Executive Vice President of Business Development at Nanology Labs, an IND-stage spinout from the University of Toronto and UHN, which is developing a breakthrough therapy to treat solid tumor cancers resistant to radiotherapy.
In 2020 he started Taking Terms, a service to help build biotech ventures coming out of the Ontario research ecosystem. Previously, he served as the Director of Technology Development and Commercialization at UHN from 2014-2020. Prior to that, he has served in several executive leadership roles at organizations such as the South Korean government, and AstraZeneca Pharmaceuticals.
John received his PhD in Microbiology & Immunology from the University of California at Berkeley, and his MBA from the Le Bow College of Business at Drexel University.